Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cohesion CE-marks its CoStasis surgical hemostat:

This article was originally published in Clinica

Executive Summary

Palo Alto, California-based Cohesion Technologies has CE-marked its CoStasis Surgical Hemostat. The product consists of thrombin, collagen and autologous fibrinogen, and is designed to control diffuse bleeding during surgical procedures. It is used in a spray form to allow delivery over large or more detailed surface areas. CoStasis remains intact while the wound heals and is then absorbed and eliminated by the body. The patient's own plasma is used in the product, which reduces occurrence of disease transmission.

Topics

UsernamePublicRestriction

Register

MT082239

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel